Lazard Asset Management LLC bought a new position in Adicet Bio, Inc. (NASDAQ:ACET – Get Rating) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,669 shares of the company’s stock, valued at approximately $82,000.
A number of other hedge funds have also recently modified their holdings of the stock. Cowen AND Company LLC boosted its stake in shares of Adicet Bio by 62.9% in the second quarter. Cowen AND Company LLC now owns 2,443,780 shares of the company’s stock worth $35,679,000 after buying an additional 943,725 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in Adicet Bio in the 2nd quarter worth about $919,000. Candriam S.C.A. acquired a new position in Adicet Bio in the 2nd quarter worth about $18,740,000. Victory Capital Management Inc. acquired a new position in Adicet Bio in the 2nd quarter worth about $337,000. Finally, SG Americas Securities LLC acquired a new position in Adicet Bio in the 2nd quarter worth about $160,000.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the company. Truist Financial reduced their price target on Adicet Bio to $27.00 in a report on Tuesday, August 23rd. Wedbush upped their price target on Adicet Bio to $30.00 in a report on Wednesday, November 16th. JPMorgan Chase & Co. assumed coverage on Adicet Bio in a report on Wednesday, September 21st. They issued an “overweight” rating and a $23.00 price target for the company. Finally, StockNews.com initiated coverage on Adicet Bio in a report on Wednesday, October 12th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $27.75.
Insider Activity at Adicet Bio
Adicet Bio Price Performance
Shares of Adicet Bio stock opened at $17.20 on Thursday. The business has a 50 day simple moving average of $16.54 and a two-hundred day simple moving average of $15.10. Adicet Bio, Inc. has a 12 month low of $9.29 and a 12 month high of $21.87. The stock has a market capitalization of $737.04 million, a P/E ratio of -12.13 and a beta of 2.14.
Adicet Bio Profile
Adicet Bio, Inc, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
- Get a free copy of the StockNews.com research report on Adicet Bio (ACET)
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.